Jct.Bk

JCT.BK maintains a strong liquidity position with a current ratio of 10.28, indicating a significant buffer of current assets over current liabilities. The company holds THB 171,741,640 in cash and equivalents, and its operating cash flow of THB 137,375,900 supports ongoing operations without reliance on external financing. The absence of long-term debt further enhances its financial flexibility.

In terms of profitability, JCT.BK reports a return on equity (ROE) of 8.05% and a return on assets (ROA) of 7.07%, which are strong indicators of efficient capital utilization and asset management. These metrics suggest the company is generating solid returns relative to its equity and total assets.

JCT.BK's revenue is concentrated within the Pharmaceuticals segment, with no disclosed geographic diversification in the provided data. The company's revenue of THB 872,188,670 is entirely attributed to its core pharmaceutical operations, indicating a focused business model.

The company's growth trajectory is supported by its strong operating income of THB 132,326,260 and net income of THB 115,989,880. While specific future growth projections are not provided, the company's consistent revenue and profitability suggest a stable growth path.

JCT.BK presents a low risk of dilution, with no immediate filing-based liquidity or dilution flags detected. The company's capital structure is robust, with no long-term debt and a high current ratio, reducing the likelihood of equity dilution through new financing.

Recent financial filings and transcripts indicate no significant events that would impact the company's financial stability or strategic direction. The company's consistent performance and lack of immediate financial risks suggest a stable operating environment.